Herzog C R, Crist K A, Sabourin C L, Kelloff G J, Boone C W, Stoner G D, You M
Division of Nutritional Carcinogenesis, American Health Foundation, Valhalla, New York, USA.
Mol Carcinog. 2001 Mar;30(3):159-68. doi: 10.1002/mc.1024.
Loss of heterozygosity (LOH) on chromosome 3p is a common event in cervical cancer and typically occurs in a dispersed pattern involving several loci. This implies that more than one resident tumor-suppressor gene is involved in the genesis of these tumors; however, specific targets remain to be identified. The region of 3p14.2-pter encompasses a region of frequent loss and contains at least three tumor-suppressor genes: fragile histidine triad (FHIT), transforming growth factor-beta receptor II (T beta R-II), and Von Hippel-Lindau. To identify those loci within 3p14.2-pter that are important in cervical cancer, invasive tumors were first subjected to high-density LOH analysis. With 25 microsatellite markers, LOH was detected in seven of 15 cervical carcinomas (47%). Losses always included markers mapping to 3p22, and markers at this location were exclusively lost in two tumors, implicating this as a site of a cervical tumor-suppressor gene. Because it is a known tumor-suppressor gene located at 3p22 and thus a potential target for inactivation in these tumors, the T beta R-II gene was subsequently screened for mutation and altered expression levels. Whereas no tumor-derived mutations were detected in any of the tumors, six of ten tumors showed T beta R-II transcript levels reduced by > or = 50% when compared with normal cervical epithelium. Nine of 15 (60%) tumors exhibited LOH at 3p22 or reduced expression of T beta R-II, suggesting that reduced T beta R-II levels contribute to cervical tumorigenesis. Two cases exhibited silent germline polymorphisms of T beta R-II: one corresponding to a C1167T transversion and the other to an A1266G transition. The FHIT gene, which is located at 3p14.2, also frequently incurred LOH and abnormal transcription in these tumors. LOH of FHIT was observed in five of the 15 tumors analyzed. Neither mutations nor homozygous deletions of FHIT were detected in the tumors. However, aberrantly short transcripts of the FHIT gene were evident in six of nine (67%) tumors. Only one of these also displayed LOH, indicating that this gene was altered in at least 10 of 15 (67%) tumors. These results provide evidence that the inactivation of two known tumor-suppressor genes, TbetaR-II and FHIT, on chromosome 3p is involved in cervical carcinogenesis. Mol. Carcinog. 30:159--168, 2001.
3号染色体短臂杂合性缺失(LOH)是宫颈癌中常见的事件,通常以分散模式发生,涉及多个位点。这意味着这些肿瘤的发生涉及不止一个常驻肿瘤抑制基因;然而,具体靶点仍有待确定。3p14.2 - pter区域存在频繁缺失,并且包含至少三个肿瘤抑制基因:脆性组氨酸三联体(FHIT)、转化生长因子β受体II(TβR - II)和冯·希佩尔 - 林道基因。为了确定3p14.2 - pter区域内对宫颈癌重要的那些位点,首先对浸润性肿瘤进行了高密度LOH分析。使用25个微卫星标记,在15例宫颈癌中的7例(47%)检测到了LOH。缺失总是包括定位到3p22的标记,并且该位置的标记在两个肿瘤中完全缺失,这表明此处是宫颈癌肿瘤抑制基因的一个位点。由于TβR - II基因是位于3p22的已知肿瘤抑制基因,因此是这些肿瘤中失活的潜在靶点,随后对其进行了突变和表达水平改变的筛查。虽然在任何肿瘤中均未检测到肿瘤来源的突变,但与正常宫颈上皮相比,10例肿瘤中有6例显示TβR - II转录水平降低≥50%。15例肿瘤中有9例(60%)在3p22处出现LOH或TβR - II表达降低,这表明TβR - II水平降低有助于宫颈癌的发生。两例表现出TβR - II的沉默种系多态性:一例对应于C1167T颠换,另一例对应于A1266G转换。位于3p14.2的FHIT基因在这些肿瘤中也经常发生LOH和异常转录。在分析的15例肿瘤中有5例观察到FHIT的LOH。在肿瘤中未检测到FHIT的突变或纯合缺失。然而,9例(67%)肿瘤中有6例FHIT基因转录本明显异常短小。其中只有1例也显示出LOH,这表明该基因在15例肿瘤中的至少10例(67%)中发生了改变。这些结果提供了证据,证明3号染色体短臂上两个已知的肿瘤抑制基因TβR - II和FHIT的失活与宫颈癌发生有关。《分子致癌学》30:159 - 168,2001年。